

Supplementary Table 4. MS cohort characteristics by treatment category and gender

Treatment category	Treated with anti-CD20 monoclonal antibody		Untreated	
	male	female	male	female
#	23/46 (50%)	23/46 (50%)	5/26 (19%)	21/26 (81%)
Demographic and clinical characteristics				
Clinical phenotype	RRMS 7 (30%) PMS 16 (70%)	RRMS10 (44%) PMS 13 (56%)	RRMS 2 (40%) PMS 3 (60%)	RRMS 8 (38%) PMS 13 (62%)
Mean age, years (SD)	41 (±11)	44 (±11)	57 (±10)	50 (±9)
Mean disease duration, years (SD)	8 (±8)	12 (±9)	11 (±13)	16 (±10)
# patients with previous DMT ^{&}	13/23 (57%)	15/23 (65%)	3/5 (60%)	11/26 (42%)
Median EDSS at baseline (range)	RRMS 2.5 (4.5-0) PMS 5 (8-2)	RRMS 1.5 (5.5-0) PMS 5.5 (6.5-2)	RRMS 1 (6.5-0) PMS 3.5 (6-3)	RRMS 1.5 (3-0) PMS 5 (7-2.5)
Median EDSS last-MRI fu. (range)	RRMS 3 (5-0) PMS 6 (8-1.5)	RRMS 1.5 (5.5-0) PMS 5.5 (8-2.5)	RRMS 6 (6.5-0) PMS 3 (6-0)	RRMS 1.5 (3.5-0) PMS 5 (6.5-1.5)
# patients with PIRA	7/23 (30%)	2/23 (9%)	1/5 (20%)	1/21(5%)
Mean follow-up time, months (range) [§]	23 (8-40)	22 (11-38)	32 (10-83)	30 (6-69)
Mean number of treatment infusions (SD) ^α	4 (±1)	4 (±1)	-	-
# patients with ≥1 PRL (%)	21/23 (91%)	15/23 (65%)	4/5 (80%)	7/21 (33%)

^α Mean number of treatment infusions: the first 2 infusion (normally 15 days apart) were counted as 1.

[§]Average post-treatment (for anti-CD20 treated patients) or post baseline MRI acquisition (for untreated patients) follow-up time.

[&] Number of patients having received another DMT before inclusion in the study (e.g. before the baseline MRI acquisition).

Abbreviations: RRMS: relapsing-remitting MS; PMS: progressive MS (including primary and secondary progressive MS patients); DMT: disease modifying treatment; EDSS: Expanded Disability Status Scale; MRI: magnetic resonance imaging; PIRA: progression independent of relapse activity; PRL: paramagnetic rim lesion; QSM: quantitative susceptibility mapping; SD: standard deviation.